Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Search By Topic

Regulatory

101 Articles available
Drug Pricing

New Senate Bill Includes Amendment on Drug Pricing in Ads for Prescription Meds

PAO-M08-18-NI-026
Regulatory Approval

CERENOVUS Receives European Regulatory Approval For BRAVO Flow Diverter to Treat Intracranial Aneurysms

PR-M08-18-NI-088
Regulatory

Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen

PR-M08-18-NI-093
Regulatory

China to Accelerate Review of 48 Foreign Drugs

PAO-M08-18-NI-013
China

Big Pharma Companies Taking New Drugs to China First

PAO-M08-18-NI-010
Regulatory

Reducing Time to Market with Targeted Regulatory Affairs Support

PAO-06-18-CL-003
Regulatory

Compliance at Hovione, Annual Inspection Review

PR-M03-18-NI-037
Regulatory

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

PR-M01-18-NI-060
Research

Medical Research Collaborating Center Selects Medidata to Meet Global Regulatory Requirements During Clinical Trials

PR-M01-18-NI-037
Regulatory

FDA Approves New Pfizer Biosimilar

PR-M12-17-NI-010
Regulatory

Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics

PR-M12-17-NI-009
Regulatory

FDA Approves Admelog, The First Short-Acting "Follow-On" Insulin Product To Treat Diabetes

PR-M12-17-NI-008
Regulatory

Booklet Label Combines Tamper-Protection And Drug Information

PR-M12-17-NI-004
Oncology

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

PR-M12-17-NI-006
Biosimilars

Boehringer Ingelheim’s Adalimumab Biosimilar Wins First EU Approval

PAO-M11-17-NI-045
Drug Development

Small Molecule Cancer Combination Therapy Receives Second Patent

PAO-M11-17-NI-031
FDA

First Treatment for Rare Blood Disorder Approved by FDA

PAO-M11-17-NI-026
Diagnostics

Ultrasound Transducer from Butterfly Network Receives FDA Approval for 13 Applications

PAO-M11-17-NI-023
FDA

FDA, European Regulators Align for More Efficient GMP Inspections

PAO-M11-17-NI-002
FDA Approval

Calquence, AstraZeneca’s BTK Inhibitor Approved by FDA

PAO-M11-17-NI-001
Regulatory

No Clinically Meaningful Difference: The Upward Trend of Biosimilars

PAP-Q4-17-FA-001
CAR-T

Breakthrough CAR-T Immunotherapy Approved

PAO-M10-17-NI-037
Drug Pricing

California Moves to Increase Transparency of Prescription Drug Pricing

PAO-M10-17-NI-030
FDA Approval

FDA Expands 510(k) Clearance for NuVasive’s Limb Lengthening Platform to Include Bone Transport

PAO-M10-17-NI-022
FDA Approval

FDA Approves New, Implantable Sleep Apnea Treatment

PAO-M10-17-NI-016
FDA

FDA Grants Priority Review to Gilotrif® For Uncommon EGFR Mutations in Advanced NSCLC

PR-M10-17-NI-002
FDA Approval

Novartis Receives First Ever FDA Approval For A CAR-T Cell Therapy, Kymriah(TM) (CTL019)

PR-M08-17-NI-010
FDA

FDA Finalizes Emerging Drug Manufacturing Technology Guidance

PAO-M10-17-NI-012
Innovation

New Plant Will Supply Large Numbers of Genetically Modified Mosquitos

PAO-M10-17-NI-008
FDA Approval

Eli Lilly Gets Early Approval for Breast Cancer Drug

PAO-M10-17-NI-006
FDA Approval

FDA Approves Grifols’ Prolastin-C Liquid

PAO-M09-17-NI-032
Biosimilar

FDA Approves First Biosimilar Treatment for Multiple Cancers

PAO-M09-17-NI-030
FDA

GSK Shingles Vaccine Recommended for Approval by FDA Panel

PAO-M09-17-NI-027
Serialization

PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

PR-M09-17-NI-008
Innovation

FDA Green Lights Mobile App to Help Treat Drug Abuse

PAO-M09-17-NI-022
ADC

Pfizer Gets Second ADC Approval in 2017

PAO-M09-17-NI-019
Innovation

Women Gain New Control Over Mammogram Discomfort

PAO-M09-17-NI-016
FDA

Collaborations within FDA Intended to Improve Facility Inspections and Facilitate Drug Approvals

PAO-M09-17-NI-010
FDA

FDA’s Gottlieb Weighs in on the Drug Quality and Security Act (DQSA)

PAO-M06-17-NI-018
Regulatory

Implications of Serialization for the U.S. Pharma Industry

PAP-Q2-17-CL-001
Regulation

Serialization: The First Steps In Sales Unit Traceability and Data Management

PAP-Q2-17-CL-002
CDMO

Supporting the Tech Transfer Continuum for Cell & Gene Therapies

PAP-Q2-17-CL-003
Regulatory

Moving Quality to the Forefront Brings Measurable Results

PAP-Q2-17-CL-008
Regulatory

The Mission of Commissioning Agents, Inc.

RJ Filannino, Manager of Technical Services, Mid-Atlantic, Commisioning Agents Inc. (CAI)

PTV-M03-17-IN-004
Clinical Trials

Advancing Clinical Trial Efficiency with Electronic Informed Consent

APR-M03-17-NI-001
API

Anticipating Future Guidelines By Utilizing The Latest Technologies In Particle Characterization

POP-M03-17-NI-001
CRO

What’s New in Bioanalysis?

Chad Briscoe, Executive Director, PRA Health Sciences

PTV-M11-16-AP-019
Manufacturing

Continuous Processing

Stephen Sirabian, Executive Vice President, E/E Division, Glatt Air Techniques

PTV-M01-17-NS-002
Regulatory

FDA Issues Warning to Two More Companies

PAO-M03-17-NI-013
Regulatory

FDA, EMA Complete Mutual Recognition Journey

PAO-M03-17-NI-006
Equipment

Q: How is the Need to Provide Local Drug-Product Supply in Multiple Regions Around the World Impacting Pharmaceutical Manufacturing Facility and Equipment Design?

PAP-Q1-17-RT-002
API

Q: What will be the Impact of the Requirements that Drug Manufacturers Gain a Similar Level of Supply Chain Understanding for Excipients as they Must Have for APIs?

PAP-Q1-17-RT-005
Equipment

Advancing Solid Dose Processing Efficiency and Effectiveness

PAP-Q1-17-CL-008
API

Experience and Expertise Facilitate Controlled Substance Manufacturing

PAP-Q1-17-CL-004
Clinical Trials

AAPS Expedited Pathways

PAO-M11-16-NI-002
Biologics

INNOVATION: Creating Solutions for Healthcare’s Ambitious Agenda

PAP-Q04-16-FA-001
CDMO

Q: What is Your Perception of the State of Serialization in Your Sector of the Pharma Industry?

PAP-Q04-16-RT-003
Supply Chain

Perspectives on Product Pricing Strategy and Practice

PAP-Q04-16-NC-001
Clinical Trials

Speed-to-Market: Process and Capacity on Demand

PAP-Q04-16-CL-014
CDMO

Q: What Are You Doing to Become a Premier Outsourcing Partner in the Context of FDA’s Recent Shift to a Focus on Quality Culture Rather than Just Metrics?

PAP-Q04-16-RT-002
CDMO

Achieving Successful Treatment Outcomes Through the Delivery of Manufacturing Services

PAP-Q04-16-CL-012
CDMO

Rx-360: An Industry Group Like No Other

PAP-Q04-16-CL-007
Outsourcing

Shaping the Conversation – Bringing Voice & Value

PAP-Q04-16-ED-001
API

Process Performance Qualification Prep: a Strategic Approach Leads to Success

PAP-Q03-16-CL-008
Aggregation

Track & Trace Systems for Serialization and Aggregation

PAP-Q03-16-CL-012
Excipients

What Are the Latest Guidelines for Excipients?

POP-M07-16-NI-001
EDC

The Pharmaceuticals App Market is Comparatively Weak and Inherently Limited, but Considerable Potential Exists

APR-M07-16-NI-001
CDMO

Customer Experience: Key to Growth in the Outsourced Services Industry

PAP-Q1-16-IC-001
API

Continuous Processing: Meeting the Need for New Manufacturing Strategies

PAP-Q1-16-CL-005
CDMO

Will Biosimilars Make a Difference for the CMO/CDMO Market?

POP-M11-15-NI-001
API

What Does It Mean to be a Full-Service CDMO?

PAP-Q4-15-CL-002
API

In-depth Process and Product Expertise – This is Key to CDMO Support of Orphan Drug and Breakthrough Therapy Development & Commercialization

PAP-Q4-15-CL-004
Formulation

Choosing the Optimal Drug Delivery System to Meet Patient Needs

PAP-Q4-15-CL-008
API

Challenges Facing Pharmaceutical Excipients

APR-M05-15-NI-001
Clinical Trials

How a CMO Can Help With Investigational New Drug Applications

PAP-APR-S01-CL-002
Excipients

Speaking the Same Language – The Gap Between the Sales Pitch and Supplier Selection Criteria – And How It Applies in the Excipients Market

APR-M03-15-NI-004
Outsourcing

Biopharmaceutical Outsourcing To CROs In Emerging Markets Surges For 2015

LSL-M03-15-NI-002
Outsourcing

Selecting An Outsourcing Partner For Vaccine Production

ICO-M03-15-NI-001
CDMO

What Does 2015 Hold For The Indian CMO Industry?

LSL-M03-15-NI-003
Biologics

Logistics Providers Strive to Fulfill Biopharma Needs – Specialty Companies Offer Advantages, but Get a Bad Rap on Price

LSL-M11-14-NI-002
Outsourcing

Sponsors Not the Only Party to Benefit from Clinical Trials in Emerging Markets

POP-M06-14-NI-001
Biologics

Pre-filled Syringe Technology Benefits Patients, Healthcare Providers and Drug Makers

CIO-M06-14-NI-001
Outsourcing

2014 Trends in Strategic Outsourcing — Changes in the Qualities that Drive Outsourcing Partner Selection

CIO-M01-14-NI-001
Outsourcing

What Can 2013 Outsourcing Trends Lead Us to Expect In 2014

LSL-M12-13-NI-001
Outsourcing

The Top CROs by Therapeutic Indication Share Strong Regulatory and Productivity Performance

LSL-M09-13-NI-001
Outsourcing

Outsourcing Clinical Research — Trends by Customer Group

LSL-M03-13-NI-001
Outsourcing

How Relevant are 483s in Terms of Compliance Perception?

CIO-M11-12-NI-001
Clinical Trials

Will A Focus On Innovation Pay Off For Custom Synthesis Providers?

CIO-M08-12-NI-001
Outsourcing

Capacity Issues and the Question: To Insource or Outsource?

LSL-M08-12-NI-001
Outsourcing

CROs & CMOs: Focusing On Innovation

LSL-M05-12-NI-001
CDMO

Process Optimization: Innovation's Role

PPO-M04-12-NI-001
Outsourcing

Outsourcing to Emerging Markets: The Effect of the European Economic Crisis

PTO-M02-12-NI-001
Outsourcing

Optimizing the Partner Selection Process for Drug Developers

LSL-M12-11-NI-002
Outsourcing

Who Should Be Doing Your Pharmaceutical Analytical Testing — a CRO or CMO?

PPO-M12-11-NI-001
Clinical Trials

Where Do Strategic Business Opportunities Lie For Mid-Tier CROs?

PCO-M10-11-NI-001
CMO

Sterile Manufacturing Opportunities

PPO-M10-11-NI-001
CMO

Contract Services Spending: Who's Spending What, and Where?

BIO-M10-11-NI-001
Clinical Trials

Benefit From Clinical Trials In Emerging Markets While Limiting Risk Exposure

LSL-M09-11-NI-001
CDMO

Customer Drivers Influencing Supplier Differentiation

PTO-M08-11-NI-001
Outsourcing

Do Companies That Offer Regulatory Support Services Score Higher On Regulatory Compliance?

LSL-M08-11-NI-001
CMO

Strong Regulatory Compliance and Reliability Indicative of Solid Partnership Choices

LSL-M06-11-NI-001
×